UBS Group
PGEN icon

UBS Group’s Precigen PGEN Stock Holding History

UBS Group’s Portfolio PGEN Stock Details PGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-154,600
Closed -$1.58M – 9349
2020
Q4 		$1.58M Hold
154,600
– – ﹤0.01% 3619
2020
Q3 		$541K Buy
+154,600
New +$734K ﹤0.01% 4122
2015
Q2 		– Sell
-105
Closed -$5K – 8751
2015
Q1 		$5K Sell
105
-3,976
-97% -$143K ﹤0.01% 8116
2014
Q4 		$107K Buy
+4,081
New +$89.5K ﹤0.01% 5640

Other funds holding PGEN

PCM
Patient Capital Management Baltimore, Maryland $3.05B AUM 42.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group's PGEN Position: Q2 2026 in Review

UBS Group increased its Precigen (PGEN) stake by 14% in Q2 2026, buying an estimated $401K and bringing the position to 778,763 shares worth $4.44M. The position accounts for ﹤0.01% of the portfolio, ranked #4295.

UBS Group first reported a position in PGEN in Q4 2014 and has held it in 47 quarters since. The position peaked at $8.07M in Q4 2015. 210 funds tracked by Wall St. Rank hold PGEN as of Q2 2026.

  • UBS Group held 778,763 shares of Precigen worth $4.44M as of Q2 2026.
  • UBS Group bought 92,679 Precigen shares in Q2 2026, an estimated $401K.
  • Precigen made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4295 holding.
  • UBS Group first reported a position in Precigen in Q4 2014 and has held it in 47 quarters since.
  • UBS Group's Precigen position peaked at $8.07M in Q4 2015.
  • 210 funds tracked by Wall St. Rank held Precigen as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.